Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) EBT Margin (2016 - 2025)

Historic EBT Margin for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to 8470.5%.

  • Northwest Biotherapeutics' EBT Margin fell 37419300.0% to 8470.5% in Q3 2025 from the same period last year, while for Sep 2025 it was 7838.42%, marking a year-over-year decrease of 34730100.0%. This contributed to the annual value of 5374.46% for FY2024, which is 22301000.0% down from last year.
  • According to the latest figures from Q3 2025, Northwest Biotherapeutics' EBT Margin is 8470.5%, which was down 37419300.0% from 12675.57% recorded in Q2 2025.
  • Northwest Biotherapeutics' EBT Margin's 5-year high stood at 1589.89% during Q1 2023, with a 5-year trough of 12675.57% in Q2 2025.
  • Over the past 5 years, Northwest Biotherapeutics' median EBT Margin value was 4726.03% (recorded in 2022), while the average stood at 5635.28%.
  • In the last 5 years, Northwest Biotherapeutics' EBT Margin surged by 2000000000bps in 2021 and then plummeted by -89216500bps in 2025.
  • Over the past 5 years, Northwest Biotherapeutics' EBT Margin (Quarter) stood at 3329.43% in 2021, then grew by 2bps to 3249.41% in 2022, then fell by -13bps to 3681.8% in 2023, then crashed by -147bps to 9085.28% in 2024, then increased by 7bps to 8470.5% in 2025.
  • Its EBT Margin stands at 8470.5% for Q3 2025, versus 12675.57% for Q2 2025 and 5043.47% for Q1 2025.